No. S 361
Medical and Elderly Care
Endowment Schemes Act
(CHAPTER 173A)
Medical and Elderly Care Endowment Schemes
(Medifund Committees)
Order 2015
In exercise of the powers conferred by section 14 of the Medical and Elderly Care Endowment Schemes Act, the Minister for Health makes the following Order:
Citation and commencement
1.  This Order may be cited as the Medical and Elderly Care Endowment Schemes (Medifund Committees) Order 2015 and comes into operation on 18 June 2015.
Medifund committees
2.—(1)  The Minister appoints the Medifund committees named in the first column of Parts 1, 2 and 3 of the Schedule for the purposes of Part 2 of the Act.
[S 51/2022 wef 11/04/2022]
[S 607/2024 wef 01/08/2024]
(2)  A Medifund committee named in the first column of Part 1 of the Schedule may —
(a)consider and approve applications under section 15 of the Act from all classes of eligible patients (other than the class of eligible patients mentioned in sub-paragraph (4)(a)) in one or more approved institutions designated in the second column of Part 1 of the Schedule corresponding to the Medifund committee; and
[S 607/2024 wef 01/08/2024]
(b)exercise the powers and perform the duties under Part 2 of the Act in relation to such approved institutions and classes of eligible patients.
[S 51/2022 wef 11/04/2022]
(3)  A Medifund committee named in the first column of Part 2 of the Schedule may —
(a)in one or more approved institutions designated in the second column of Part 2 of the Schedule corresponding to the Medifund committee, consider and approve applications under section 15 of the Act from the classes of eligible patients specified opposite to the approved institutions in the third column of Part 2 of the Schedule; and
(b)exercise the powers and perform the duties under Part 2 of the Act in relation to such approved institutions and classes of eligible patients.
[S 51/2022 wef 11/04/2022]
(4)  A Medifund committee named in the first column of Part 3 of the Schedule may —
(a)consider and approve applications under section 15 of the Act from an eligible patient who has received treatment or requires treatment involving the administration of any cell, tissue or gene therapy product from one or more approved institutions designated in the second column of Part 3 of the Schedule corresponding to the Medifund committee; and
(b)exercise the powers and perform the duties under Part 2 of the Act in relation to those approved institutions and the eligible patient.
[S 607/2024 wef 01/08/2024]
(5)  For the purposes of sub-paragraph (4), the hospital charges, fees and other expenses forming the subject matter of an application include any hospital charges, fees and other expenses incurred by the eligible patient for any other treatment received by him or her from the approved institution which does not involve the administration of any cell, tissue or gene therapy product if, and only if, such other treatment is received within the same hospitalisation period as the treatment involving the administration of any cell, tissue or gene therapy product from the approved institution.
[S 607/2024 wef 01/08/2024]
(6)  In this paragraph —
“cell, tissue or gene therapy product” has the meaning given by the First Schedule to the Health Products Act 2007;
“hospitalisation period” means the period starting on the day an eligible patient is admitted to an approved institution and ending on (and including) the day the eligible patient is discharged from the approved institution.
[S 607/2024 wef 01/08/2024]
Revocation
3.  The Medical and Elderly Care Endowment Schemes (Medifund Committees) Order 2013 (G.N. No. S 336/2013) is revoked.
Made on 5 June 2015.
TAN CHING YEE
Permanent Secretary,
Ministry of Health,
Singapore.
[MH 24:10/13 Vol. 7; AG/LLRD/SL/173A/2010/2 Vol. 2]